文献速递心境障碍

氯胺酮与电休克治疗均增加5-HT1B受体结合:多中心PET数据贝叶斯再分析

Convergent increases in serotonin 1B receptor binding following ketamine and electroconvulsive therapy: a multi-centre bayesian re-analysis of PET data.
PubMed 文献 · Mol Psychiatry · 2026-07-08

该研究对三个中心共222次[11C]AZ10419369 PET测量进行多中心贝叶斯再分析,纳入治疗前后接受氯胺酮(19例完成者)、生理盐水安慰剂(10例)或ECT(13例完成者)的重性抑郁障碍患者。结果显示氯胺酮和ECT分别使5-HT1B受体结合增加6.4%(95%CI:3.1-9.6%)和9.3%(95%CI:4.3-14.2%),氯胺酮所致变化与安慰剂有统计学差异,探索性跨中心比较提示ECT所致变化亦可与安慰剂区分。

要点

  • 氯胺酮治疗后5-HT1B受体结合增加6.4%(95%CI:3.1-9.6%)。
  • ECT治疗后5-HT1B受体结合增加9.3%(95%CI:4.3-14.2%)。
  • 受体结合变化与个体症状改善无关联。

核心结论

  • 氯胺酮和ECT虽主要靶点不同,但均引起5-HT1B受体结合增加,提示二者可能汇聚于5-羟色胺系统的相似下游变化。

研究设计与样本

  • 多中心PET数据再分析,共222次[11C]AZ10419369 PET测量,来自三个中心。
  • 纳入重性抑郁障碍患者治疗前后PET:氯胺酮组19例完成者、生理盐水安慰剂组10例、ECT组13例完成者。
  • 采用分层贝叶斯方法(SiMBA)利用全数据集改善参数估计并实现跨中心数据协调。

主要发现

  • 氯胺酮治疗后5-HT1B受体结合增加6.4%(95%CI:3.1-9.6%)。
  • ECT治疗后5-HT1B受体结合增加9.3%(95%CI:4.3-14.2%)。
  • 氯胺酮所致变化与安慰剂有统计学差异。
  • 探索性跨中心比较提示ECT所致变化亦可与安慰剂区分。
  • 上述变化与个体症状改善无关联。

临床怎么用

  • 提示氯胺酮和ECT可能通过5-羟色胺系统下游共同通路发挥抗抑郁作用,为机制研究提供方向。
  • 5-HT1B受体结合变化与症状改善无关联,不宜作为个体疗效预测指标。

局限性

  • ECT与安慰剂的比较仅为探索性跨中心分析,非预设主要比较。
  • 各治疗组完成者样本量较小(氯胺酮19例、安慰剂10例、ECT13例)。
  • 受体结合变化与个体症状改善无关联,机制与临床获益的关系尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The serotonin 1B receptor can be studied in vivo with PET using [11C]AZ10419369, and has been linked to both the pathophysiology and treatment of major depressive disorder (MDD). Ketamine and electroconvulsive therapy (ECT) both exert rapid and potent antidepressive effects, and although these treatments may not act directly on the serotonin system, they both cause dose-dependent increases in serotonin levels, and there is convergent evidence suggesting that the serotonin system may be important for their mechanisms of action. In this study, we re-analysed a multi-centre dataset of 222 [11C]AZ10419369 PET measurements from three centres, including MDD patients examined with PET both before and after treatment with ketamine (n = 19 completers), saline placebo (n = 10), or ECT (n = 13 completers). Using a hierarchical Bayesian approach (SiMBA) that takes advantage of the full dataset to improve parameter estimation and enable data harmonisation across centres, we demonstrate large increases in 5-HT1BR binding following both ketamine (6.4%, 95% CI: 3.1-9.6%) and ECT (9.3%, 95% CI: 4.3-14.2%). Ketamine-induced changes were statistically distinguishable from placebo, and an exploratory cross-centre comparison enabled by the data harmonisation within the combined modelling framework, suggests that ECT-induced changes are also distinguishable from placebo. These changes were not associated with individual symptom improvement. These findings suggest that despite differences in the pri-mary target of these rapid acting treatments for depression, they may converge on similar downstream changes to the serotonin system.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Matheson GJ, Lundberg J, Gärde M, et al. Convergent increases in serotonin 1B receptor binding following ketamine and electroconvulsive therapy: a multi-centre bayesian re-analysis of PET data. Mol Psychiatry. 2026. PMID: 42420418. doi:10.1038/s41380-026-03704-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。